Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women

A. B. Moscicki, C. M. Wheeler, B. Romanowski, J. Hedrick, S. Gall, Daron Gale Ferris, S. Poncelet, T. Zahaf, P. Moris, B. Geeraerts, D. Descamps, A. Schuind

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Vaccines are now available for the prevention of HPV-16/18-related cervical infections and pre-cancers, primarily targeting adolescent girls. Since the risk of HPV exposure potentially persists throughout a woman's sexual life, vaccine-derived immunity should be long-term. The current study, HPV-024 (NCT00546078, http://clinicaltrials.gov), assessed the immune memory in North American women who received three doses of HPV-16/18 AS04-adjuvanted vaccine 7 years earlier in HPV-001 (NCT00689741). Methods: Women vaccinated in HPV-001 received a 4th-dose of the HPV-16/18 vaccine (024-4DV group, N=65). Post 4th-dose immune responses were compared with post 1st-dose immune responses in cross-vaccination controls (024-3DV group, N=50). Reactogenicity was compared between the 4th-dose and the 1st-dose administration. Results: Pre 4th-dose, 100% of subjects in the 024-4DV group remained seropositive for anti-HPV-16/18 antibodies (ELISA). Compared to pre 4th-dose, GMTs for anti-HPV-16 and anti-HPV-18 antibodies were respectively 9.3-fold and 8.7-fold higher at day 7, and 22.7-fold and 17.2-fold higher at month 1. Compared to post 1st-dose, GMTs for anti-HPV-16 and anti-HPV-18 were respectively 80.5-fold and 205.4-fold higher at day 7, and 11.8-fold and 20.5-fold higher at month 1. Furthermore, 68.2% and 77.3% of women had HPV-16/18 specific memory B-cells, respectively, pre 4th-dose, rising to 100% one month post 4th-dose vaccination. The 4th-dose was generally well tolerated. Conclusion: A 4th-dose of HPV-16/18 AS04-adjuvanted vaccine triggered a rapid and strong anamnestic response in previously vaccinated women, demonstrating vaccine-induced immune memory.

Original languageEnglish (US)
Pages (from-to)234-241
Number of pages8
JournalVaccine
Volume31
Issue number1
DOIs
StatePublished - Dec 17 2012

Fingerprint

Human papillomavirus 16
Human papillomavirus 18
Vaccines
immune response
vaccines
dosage
Vaccination
B-Lymphoid Precursor Cells
Antibodies
vaccination
Immunity
Enzyme-Linked Immunosorbent Assay
antibodies
B-lymphocytes

Keywords

  • Anamnestic response
  • Cervical cancer
  • HPV infection
  • HPV vaccine
  • Sustained immunity

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women. / Moscicki, A. B.; Wheeler, C. M.; Romanowski, B.; Hedrick, J.; Gall, S.; Ferris, Daron Gale; Poncelet, S.; Zahaf, T.; Moris, P.; Geeraerts, B.; Descamps, D.; Schuind, A.

In: Vaccine, Vol. 31, No. 1, 17.12.2012, p. 234-241.

Research output: Contribution to journalArticle

Moscicki, AB, Wheeler, CM, Romanowski, B, Hedrick, J, Gall, S, Ferris, DG, Poncelet, S, Zahaf, T, Moris, P, Geeraerts, B, Descamps, D & Schuind, A 2012, 'Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women', Vaccine, vol. 31, no. 1, pp. 234-241. https://doi.org/10.1016/j.vaccine.2012.09.037
Moscicki, A. B. ; Wheeler, C. M. ; Romanowski, B. ; Hedrick, J. ; Gall, S. ; Ferris, Daron Gale ; Poncelet, S. ; Zahaf, T. ; Moris, P. ; Geeraerts, B. ; Descamps, D. ; Schuind, A. / Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women. In: Vaccine. 2012 ; Vol. 31, No. 1. pp. 234-241.
@article{b138b896be0f435f98554a0ad07b6b18,
title = "Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women",
abstract = "Background: Vaccines are now available for the prevention of HPV-16/18-related cervical infections and pre-cancers, primarily targeting adolescent girls. Since the risk of HPV exposure potentially persists throughout a woman's sexual life, vaccine-derived immunity should be long-term. The current study, HPV-024 (NCT00546078, http://clinicaltrials.gov), assessed the immune memory in North American women who received three doses of HPV-16/18 AS04-adjuvanted vaccine 7 years earlier in HPV-001 (NCT00689741). Methods: Women vaccinated in HPV-001 received a 4th-dose of the HPV-16/18 vaccine (024-4DV group, N=65). Post 4th-dose immune responses were compared with post 1st-dose immune responses in cross-vaccination controls (024-3DV group, N=50). Reactogenicity was compared between the 4th-dose and the 1st-dose administration. Results: Pre 4th-dose, 100{\%} of subjects in the 024-4DV group remained seropositive for anti-HPV-16/18 antibodies (ELISA). Compared to pre 4th-dose, GMTs for anti-HPV-16 and anti-HPV-18 antibodies were respectively 9.3-fold and 8.7-fold higher at day 7, and 22.7-fold and 17.2-fold higher at month 1. Compared to post 1st-dose, GMTs for anti-HPV-16 and anti-HPV-18 were respectively 80.5-fold and 205.4-fold higher at day 7, and 11.8-fold and 20.5-fold higher at month 1. Furthermore, 68.2{\%} and 77.3{\%} of women had HPV-16/18 specific memory B-cells, respectively, pre 4th-dose, rising to 100{\%} one month post 4th-dose vaccination. The 4th-dose was generally well tolerated. Conclusion: A 4th-dose of HPV-16/18 AS04-adjuvanted vaccine triggered a rapid and strong anamnestic response in previously vaccinated women, demonstrating vaccine-induced immune memory.",
keywords = "Anamnestic response, Cervical cancer, HPV infection, HPV vaccine, Sustained immunity",
author = "Moscicki, {A. B.} and Wheeler, {C. M.} and B. Romanowski and J. Hedrick and S. Gall and Ferris, {Daron Gale} and S. Poncelet and T. Zahaf and P. Moris and B. Geeraerts and D. Descamps and A. Schuind",
year = "2012",
month = "12",
day = "17",
doi = "10.1016/j.vaccine.2012.09.037",
language = "English (US)",
volume = "31",
pages = "234--241",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women

AU - Moscicki, A. B.

AU - Wheeler, C. M.

AU - Romanowski, B.

AU - Hedrick, J.

AU - Gall, S.

AU - Ferris, Daron Gale

AU - Poncelet, S.

AU - Zahaf, T.

AU - Moris, P.

AU - Geeraerts, B.

AU - Descamps, D.

AU - Schuind, A.

PY - 2012/12/17

Y1 - 2012/12/17

N2 - Background: Vaccines are now available for the prevention of HPV-16/18-related cervical infections and pre-cancers, primarily targeting adolescent girls. Since the risk of HPV exposure potentially persists throughout a woman's sexual life, vaccine-derived immunity should be long-term. The current study, HPV-024 (NCT00546078, http://clinicaltrials.gov), assessed the immune memory in North American women who received three doses of HPV-16/18 AS04-adjuvanted vaccine 7 years earlier in HPV-001 (NCT00689741). Methods: Women vaccinated in HPV-001 received a 4th-dose of the HPV-16/18 vaccine (024-4DV group, N=65). Post 4th-dose immune responses were compared with post 1st-dose immune responses in cross-vaccination controls (024-3DV group, N=50). Reactogenicity was compared between the 4th-dose and the 1st-dose administration. Results: Pre 4th-dose, 100% of subjects in the 024-4DV group remained seropositive for anti-HPV-16/18 antibodies (ELISA). Compared to pre 4th-dose, GMTs for anti-HPV-16 and anti-HPV-18 antibodies were respectively 9.3-fold and 8.7-fold higher at day 7, and 22.7-fold and 17.2-fold higher at month 1. Compared to post 1st-dose, GMTs for anti-HPV-16 and anti-HPV-18 were respectively 80.5-fold and 205.4-fold higher at day 7, and 11.8-fold and 20.5-fold higher at month 1. Furthermore, 68.2% and 77.3% of women had HPV-16/18 specific memory B-cells, respectively, pre 4th-dose, rising to 100% one month post 4th-dose vaccination. The 4th-dose was generally well tolerated. Conclusion: A 4th-dose of HPV-16/18 AS04-adjuvanted vaccine triggered a rapid and strong anamnestic response in previously vaccinated women, demonstrating vaccine-induced immune memory.

AB - Background: Vaccines are now available for the prevention of HPV-16/18-related cervical infections and pre-cancers, primarily targeting adolescent girls. Since the risk of HPV exposure potentially persists throughout a woman's sexual life, vaccine-derived immunity should be long-term. The current study, HPV-024 (NCT00546078, http://clinicaltrials.gov), assessed the immune memory in North American women who received three doses of HPV-16/18 AS04-adjuvanted vaccine 7 years earlier in HPV-001 (NCT00689741). Methods: Women vaccinated in HPV-001 received a 4th-dose of the HPV-16/18 vaccine (024-4DV group, N=65). Post 4th-dose immune responses were compared with post 1st-dose immune responses in cross-vaccination controls (024-3DV group, N=50). Reactogenicity was compared between the 4th-dose and the 1st-dose administration. Results: Pre 4th-dose, 100% of subjects in the 024-4DV group remained seropositive for anti-HPV-16/18 antibodies (ELISA). Compared to pre 4th-dose, GMTs for anti-HPV-16 and anti-HPV-18 antibodies were respectively 9.3-fold and 8.7-fold higher at day 7, and 22.7-fold and 17.2-fold higher at month 1. Compared to post 1st-dose, GMTs for anti-HPV-16 and anti-HPV-18 were respectively 80.5-fold and 205.4-fold higher at day 7, and 11.8-fold and 20.5-fold higher at month 1. Furthermore, 68.2% and 77.3% of women had HPV-16/18 specific memory B-cells, respectively, pre 4th-dose, rising to 100% one month post 4th-dose vaccination. The 4th-dose was generally well tolerated. Conclusion: A 4th-dose of HPV-16/18 AS04-adjuvanted vaccine triggered a rapid and strong anamnestic response in previously vaccinated women, demonstrating vaccine-induced immune memory.

KW - Anamnestic response

KW - Cervical cancer

KW - HPV infection

KW - HPV vaccine

KW - Sustained immunity

UR - http://www.scopus.com/inward/record.url?scp=84870532430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870532430&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2012.09.037

DO - 10.1016/j.vaccine.2012.09.037

M3 - Article

C2 - 23063422

AN - SCOPUS:84870532430

VL - 31

SP - 234

EP - 241

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 1

ER -